Orgenesis Schedules Third Quarter 2021 Business Update Conference Call

Rhea-AI Summary

Orgenesis Inc (NASDAQ: ORGS) announced a conference call scheduled for 8:30 AM ET on November 4, 2021, to discuss corporate progress and recent developments. The call can be accessed via telephone or through a webcast. A replay will be available post-call on the Company’s Investor Events website. Orgenesis specializes in cell and gene therapies, leveraging its POCare Platform to deliver affordable and accessible treatment solutions at the point of care. This framework includes licensed therapeutics, automated technology systems, and a collaborative network aimed at enhancing patient care.

Positive

• Scheduled a conference call to discuss corporate progress, signaling transparency and engagement with investors.
• The POCare Platform aims to unlock affordable cell and gene therapies, enhancing market competitiveness.
• Collaboration with global partners through the POCare Network facilitates broader patient access.

Negative

• None.

GERMANTOWN, Md., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it plans to host a conference call at 8:30 AM Eastern Time on Thursday, November 4, 2021 to discuss the Company’s corporate progress and other developments.

The conference call will be available via telephone by dialing toll free 877-545-0320 for U.S. callers or for international callers +1 973-528-0002 and by entering access code: 236477. A webcast of the call may be accessed at https://www.webcaster4.com/Webcast/Page/2585/43447 or on the Company’s Investor Events section of the website here.

A webcast replay will be available on the Company’s Investor Events section of the website (https://ir.orgenesis.com/events#/) through Friday, November 4, 2022. A telephone replay of the call will be available approximately one hour following the call, through Thursday, November 18, 2021 and can be accessed by dialing 877-481-4010 for U.S. callers or +1 919-882-2331 for international callers and entering conference ID: 43447.

About Orgenesis
Orgenesis is a global biotech company working to unlock the full potential of cell and gene therapies (CGTs) in an affordable and accessible format at the point of care. The Orgenesis POCare Platform is comprised of three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. Orgenesis identifies promising new therapies and leverages its POCare Platform to provide a rapid, globally harmonized pathway for these therapies to reach and treat large numbers of patients at lowered costs through efficient, scalable, and decentralized production. The POCare Network brings together patients, doctors, industry partners, research institutes and hospitals worldwide to achieve harmonized, regulated clinical development and production of the therapies. Learn more about the work Orgenesis is doing at www.orgenesis.com.

Contact for Orgenesis:
David Waldman
Crescendo Communications, LLC
Tel: 212-671-1021

FAQ

What is the date and time of the upcoming Orgenesis conference call?

The Orgenesis conference call is scheduled for November 4, 2021, at 8:30 AM ET.

How can I access the Orgenesis conference call?

The conference call can be accessed by dialing 877-545-0320 for U.S. callers or +1 973-528-0002 for international callers, using access code 236477.

Will there be a replay available for the Orgenesis conference call?

Yes, a replay will be available on the Company’s Investor Events section of their website after the call.

What does the POCare Platform by Orgenesis focus on?

The POCare Platform focuses on delivering affordable and accessible cell and gene therapies at the point of care.

What is the purpose of the POCare Network?

The POCare Network aims to harmonize clinical development and production of therapies globally.